145 related articles for article (PubMed ID: 27564459)
21. Successful treatment of extramedullary blast crisis of chronic myelogenous leukemia with imatinib mesylate (STI571).
Naito K; Mori T; Miyazaki K; Tsukada Y; Ikeda Y; Okamoto S
Intern Med; 2003 Aug; 42(8):740-2. PubMed ID: 12924504
[TBL] [Abstract][Full Text] [Related]
22. An unusual case of extramedullary blast crisis in chronic myelocytic leukaemia.
Feng CS
Am J Hematol; 1988 Oct; 29(2):117-9. PubMed ID: 3189299
[TBL] [Abstract][Full Text] [Related]
23. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Mak DH; Schober WD; Chen W; Konopleva M; Cortes J; Kantarjian HM; Andreeff M; Carter BZ
Mol Cancer Ther; 2009 Sep; 8(9):2509-16. PubMed ID: 19723894
[TBL] [Abstract][Full Text] [Related]
24. Sudden blast crisis in a chronic myeloid leukemia patient during imatinib therapy.
Voican I; Vlădăreanu AM; Bumbea H; Begu M
Rom J Intern Med; 2012; 50(3):241-4. PubMed ID: 23330292
[TBL] [Abstract][Full Text] [Related]
25. Taming of the shrew--overcoming extramedullary blast crisis in the era of the new tyrosine kinase inhibitors.
Raanani P
Acta Haematol; 2013; 130(2):108-10. PubMed ID: 23548690
[No Abstract] [Full Text] [Related]
26. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
[TBL] [Abstract][Full Text] [Related]
27. Megakaryocytic blast crisis as first presentation of chronic myeloid leukemia.
Campiotti L; Grandi AM; Biotti MG; Ultori C; Solbiati F; Codari R; Venco A
Am J Hematol; 2007 Mar; 82(3):231-3. PubMed ID: 17022045
[TBL] [Abstract][Full Text] [Related]
28. Chronic myeloid leukemia with osteolytic bone involvement.
Prabhash K; Loknath D; Babu KG; Hasib AG; Biswas S; Bapsy PP
J Assoc Physicians India; 2003 Jul; 51():740-1. PubMed ID: 14621059
[No Abstract] [Full Text] [Related]
29. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Hochhaus A; Saglio G; Larson RA; Kim DW; Etienne G; Rosti G; De Souza C; Kurokawa M; Kalaycio ME; Hoenekopp A; Fan X; Shou Y; Kantarjian HM; Hughes TP
Blood; 2013 May; 121(18):3703-8. PubMed ID: 23502220
[TBL] [Abstract][Full Text] [Related]
30. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.
Alimena G; Breccia M; Latagliata R; Carmosino I; Russo E; Biondo F; Diverio D; Mancini M; Nanni M; Mandelli F
Cancer; 2006 Sep; 107(5):1008-13. PubMed ID: 16878324
[TBL] [Abstract][Full Text] [Related]
31. Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts.
Lee JJ; Kim HJ; Kim YJ; Lee S; Hwang JY; Kim YL; Kim DW
Leukemia; 2004 Sep; 18(9):1539-40. PubMed ID: 15284852
[No Abstract] [Full Text] [Related]
32. Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib.
Breccia M; Santopietro M; Cannella L; Federico V; Loglisci G; Serrao A; Petrucci L; Salaroli A; Nanni M; De Propris MS; Diverio D; Alimena G
Leuk Res; 2011 Jun; 35(6):e91-2. PubMed ID: 21316103
[No Abstract] [Full Text] [Related]
33. Extramedullary blast crisis in chronic myeloid leukemia--a case report.
Tondon R; Singh PA; Misra V; Singh M; Mohan S
Indian J Pathol Microbiol; 2005 Apr; 48(2):253-4. PubMed ID: 16758687
[TBL] [Abstract][Full Text] [Related]
34. Biphenotypic extramedullary blast crisis with MLL gene rearrangement in a case of chronic myeloid leukemia following Dasatinib therapy: An unusual case.
Juneja R; Dhamija G; Dadu T; Handoo A
Indian J Pathol Microbiol; 2016; 59(2):259-60. PubMed ID: 27166066
[No Abstract] [Full Text] [Related]
35. Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase.
Vigil CE; Wang SA; Cortes JE; Bueso-Ramos C; Verstovsek S; Shinder R; Chen SS; Katz RL; Khanna A; Esmaeli B; Manning JT; You MJ; Miranda RN
J Clin Oncol; 2011 Jun; 29(17):e514-6. PubMed ID: 21464405
[No Abstract] [Full Text] [Related]
36. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
[TBL] [Abstract][Full Text] [Related]
37. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
38. Molecular response to first line nilotinib in a patient with e19a2 BCR-ABL1 chronic myeloid leukemia.
Langabeer SE; McCarron SL; Carroll P; Kelly J; O'Dwyer M; Conneally E
Leuk Res; 2011 Sep; 35(9):e169-70. PubMed ID: 21641037
[No Abstract] [Full Text] [Related]
39. Megakaryocytic blast crisis at presentation in a pediatric patient with chronic myeloid leukemia.
Al-Shehri A; Al-Seraihy A; Owaidah TM; Belgaumi AF
Hematol Oncol Stem Cell Ther; 2010; 3(1):42-6. PubMed ID: 20231813
[TBL] [Abstract][Full Text] [Related]
40. Extramedullary blast crisis in a patient with chronic myelogenous leukemia in complete cytogenetic and molecular remission on interferon-alpha therapy.
Beedassy A; Topolsky D; Styler M; Crilley P
Leuk Res; 2000 Aug; 24(8):733-5. PubMed ID: 10936425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
